Recurrent Variceal Bleeding Due to Non-Cirrhotic Portal Hypertension in a Patient with Primary Myelofibrosis: Case Report
), Bariani Anwar(2), Anastasia Asylia Dinakrisma(3),
(1) Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo Jakarta
(2) Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo Jakarta
(3) Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/RSUPN Dr. Cipto Mangunkusumo Jakarta
Corresponding Author
Abstract
Acute upper gastrointestinal bleeding may arise from variceal or non-variceal sources. Primary myelofibrosis, classified as a subtype of myeloproliferative neoplasms, represents an uncommon clinically significant etiology of non-cirrhotic portal hypertension. The authors reported a case of a 39-year-old woman with recurrent variceal bleeding for six years. She presented with progressive weight loss, splenomegaly, and severe anemia. One year before her first episode of hematemesis, a bone marrow biopsy revealed myelofibrosis grade 2, and JAK2 V617F mutation was positive, confirming primary myelofibrosis. The treatment was discontinued due to high expense. Abdominal ultrasonography showed portal hypertension and changes suggestive of cirrhosis. She underwent successful endoscopic variceal ligation to control active bleeding, and initiation of a JAK inhibitor (ruxolitinib) was recommended for outpatient management to address the underlying disease. This case highlights that in patients presenting with variceal bleeding and portal hypertension in the absence of cirrhosis, myeloproliferative neoplasms, such as primary myelofibrosis should be considered as a differential diagnosis. This study aimed to raise awareness of primary myelofibrosis as a rare cause of non-cirrhotic portal hypertension and emphasize the importance of early recognition and targeted therapy to prevent recurrent bleeding and disease progression.
Keywords
References
Haddad FG, El Imad T, Nassani N, Kwok R, Al Moussawi H, Polavarapu A, et al. In-hospital acute upper gastrointestinal bleeding: what is the scope of the problem? World J Gastrointest Endosc. 2019;11(12):561–572.
Chen Y, Kong BB, Yin H, Liu H, Wu S, Xu T. Acute upper gastrointestinal bleeding due to portal hypertension in a patient with primary myelofibrosis: a case report. World J Clin Cases. 2024;12(15):2621–2626.
Oon SF, Singh D, Tan TH, Lee A, Noe G, Burbury K, et al. Primary myelofibrosis: spectrum of imaging features and disease-related complications. Insights Imaging. 2019;10(1):71–85.
Fulvio G, Baldini C, Mosca M, Di Paolo A, Bocci G, Palumbo GA, et al. Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardiovascular manifestations? Front Med. 2023;10:1254868.
Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v85–99.
Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, et al. Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(9):1033–1062.
McLornan DP, Psaila B, Ewing J, Innes A, Arami S, Brady J, et al. The management of myelofibrosis: a British Society for Haematology guideline. Br J Haematol. 2024;204(1):136–150.
Tefferi A. Primary myelofibrosis: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023;98(5):801–821.
Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D’Adda M, Deeg HJ, et al. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the Chronic Malignancies Working Party of the EBMT. Lancet Haematol. 2023;10(1):e59–70.
Mesa R, Harrison C, Oh ST, Gerds AT, Gupta V, Catalano J, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia. 2022;36(9):2261–2268.
Sherman MS, Samore WR, Pratt DS. Myelofibrosis and portal hypertension: the case for primary variceal screening. ACG Case Rep J. 2020;7(2):e00333.
Maki K, Haga H, Ueno Y. Management strategies for refractory esophageal varices. DEN Open. 2025;6(1):e70155.
Gan X, Yu S, Zhu M, Ning B, He S, Xie X, et al. Case report: primary myelofibrosis presenting with portal hypertension mimicking cirrhosis. Front Med. 2024;11:1–5.
Gralnek IM, Camus Duboc M, Garcia-Pagán JC, Fuccio L, Karstensen JG, Hucl T, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2022;54(11):1094–1120.
Chalasani A, Lee AU. Long-term use of subcutaneous octreotide reduces variceal bleeding in non-cirrhotic portal hypertension. Can Liver J. 2024;7(4):505–510.
Article Metrics
Abstract View
: 95 times
Download : 209 times
DOI: 10.24871/2632025293-297
Refbacks
- There are currently no refbacks.


